Immupharma PLC confident on Lupuzor’s™ future

ImmuPharma PLC (LON:IMM) CEO Dimitri Dimitriou and Chairman Tim McCarthy discuss with Proactive Investors the top-line results from their phase III trial of the drug Lupuzor™. The data revealed Lupuzor™ was more effective than the placebo (52.5% versus 44.6%) however because the response rate for those taking the non-active medication plus the “standard of care” was so high the end-point of the study was not achieved. That ‘end-point’ was a statistically significant beneficial impact from Lupuzor™. Click here to view the interview

The release as fetched from its publisher. immupharma.co.uk ↗